Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
16 hedge funds and large institutions have $1.77M invested in Hepion Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 16 → 16 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
27% less capital invested
Capital invested by funds: $2.42M → $1.77M (-$650K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$11.5K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.08K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$690 |
| 4 |
AF
Advisornet Financial
Minnetonka,
Minnesota
|
+$460 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$460 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$64.4K |
| 2 |
VF
Virtu Financial
New York
|
-$41K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.9K |
| 4 |
JP Morgan Chase
New York
|
-$2.53K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$230 |
HEPA Hedge Fund Activity: Q1 2024 in Review
16 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q1 2024, worth a combined $1.77M — down 27% from $2.42M a quarter earlier.
Fund positioning in HEPA was balanced in Q1 2024: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 3 trimmed.
The largest buyer was PNC Financial Services Group, adding an estimated $11.5K. The largest seller was Armistice Capital, cutting an estimated $64.4K.
- 16 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $1.77M of Hepion Pharmaceuticals stock for Q1 2024, down 27% quarter-over-quarter.
- 3 funds opened new Hepion Pharmaceuticals positions in Q1 2024 and 3 closed out, a net change of 0 holders.
- The largest Hepion Pharmaceuticals buyer in Q1 2024 was PNC Financial Services Group, an estimated $11.5K added.
- The largest Hepion Pharmaceuticals seller in Q1 2024 was Armistice Capital, an estimated $64.4K sold.
Based on aggregated 13F filings for Q1 2024.